SOUTH SAN FRANCISCO - AUGUST 31, 2021 - Verily, an Alphabet company, today announced that its previously announced acquisition of SignalPath, a privately held company that makes clinical research software based in Raleigh, has successfully closed.

The acquisition will strengthen and expand Verily’s existing clinical trial system and evidence generation platform, known as Baseline. The Baseline platform enables better and faster clinical trial execution, improved data aggregation and analysis, flexible study options designed for decentralized and hybrid trials, and the ability to capture real-world data, such as that generated by novel sensors and biomarkers.The SignalPath clinical trials management system (CTMS) brings state-of-the-art software to clinical research sites that improves the ease, quality and efficiency of conducting clinical research.

"Joining forces helps us to accelerate our shared ambition to make clinical research work better for everyone involved, and get medicines and devices to patients more quickly," said Amy Abernethy, MD, PhD, President of Clinical Studies Platforms at Verily. "Together, we’ll bring more comprehensive and digital solutions to the clinical trial ecosystem and modernize the way clinical research is conducted."

SignalPath co-founder and CEO Brad Hirsch, MD, and his leadership team will remain with the company and continue their work. The company’s approximately 100  employees will join Verily as part of Verily’s clinical research business. SignalPath will remain in its current Raleigh location, drawing on the abundance of healthcare and technology talent in the Triangle, and increasing Verily's footprint with a new location in North Carolina.

About Baseline

Verily's interdisciplinary team developed Baseline Platforms, designed to engage patients and clinicians in research, make it easier and faster to run clinical studies and collect high-quality, comprehensive data for all types of clinical research including site-based clinical trials, decentralized trials and more pragmatic real-world studies. For more information, please visit projectbaseline.com.

About Verily

Launched in 2015, Verily is a subsidiary of Alphabet focused on life sciences and healthcare. Verily's mission is to make the world’s health data useful so that people enjoy healthier lives. Verily develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage disease. Verily partners with leading life sciences, medical device, and government organizations, using deep hardware, software, scientific, and healthcare expertise to enable faster development, meaningful advances and deployment at scale. For more information, please visit verily.com.

About SignalPath

SignalPath was founded by Brad Hirsch, MD, and Kevin Monroe in 2014 to develop solutions to many of the challenges facing modern clinical trial management at research sites with the goal of then empowering a technology- enabled network of sites to more broadly advance the way that clinical research is conducted. The company’s clinical trial management system (CTMS) was built by researchers, for researchers, to dramatically improve the ease, quality, efficiency and profitability of trial execution. The SignalPath CTMS digitizes protocols for clients, which eliminates a significant impediment to utilization, ensures quality of trial execution, drives efficiencies and enables site staff to focus on patients. The SignalPath Research Consortium (SPARC) consists of top clinical research sites, chosen for their people, processes and track record. Through a mixture of technology solutions, training, community offerings and curated trials, SPARC sites and sponsors are able to partner to dramatically outperform competitors.

Media Contact
Robin Suchan
Verily Communications and Public Affairs
press@verily.com